| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5595644 | The American Journal of the Medical Sciences | 2017 | 20 Pages |
Abstract
Our study shows that MF therapy is associated with significantly better prognosis in patients with CC and improved survival in LC. Patients with CC on MF had fewer recurrences and metastases. Differences in metabolic pathways between CC and LC likely account for the differences in the effect of MF.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
DeAnna MD, Danielle MS, Jeffrey MA, Solomon S. MD,